Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxygen Biotherapeutics, a biotechnology company, has appointed Melville Engle to its board of directors.
Subscribe to our email newsletter
Mr Engle has broad management and financial background including six years at Dey LP, where he was the firm’s president and CEO.
Mr Engle’s background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “I’m very pleased that Mel has agreed to join our board. He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte-based products to the market.”